Mr. Speaker, on May 13, three Galien Canada awards were given out in Montreal honouring excellence in pharmaceutical research in Canada.
The 1999 award for innovative drug product went to Lipitor—atorvastatine calcium—developed and marketed by Parke-Davis Canada.
The award for research went to Dr. Jack Hirsh, Director of the Hamilton Civic Hospital Centre and Vice-President, Research of Vascular Therapeutics Inc. for his work in epidemiology and management of venous thrombo-embolic disease.
Finally, the Belleau-Nickerson award, presented to a product that has distinguished itself by making a significant contribution to pharmacotherapy and a social and economic impact, was given to Eli Lilly Canada for its product Prozac—Fluoxetine.
I would like to congratulate all the winners and encourage them in their research.